Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Abemaciclib

64570668-1f18-5f47-9f72-19e2520ed74c · FDA Approved · targets CDK4_CYCLIN_D1, CDK4_CYCLIN_D3, CDK4_CYCLIN_D2, CDK6_CYCLIN_D1, CDK6_CYCLIN_D3, CDK6_CYCLIN_D2

Abemaciclib

MeasuredReference

Abemaciclib targets CDK4_CYCLIN_D3, DYRK3, PIM3. Strongest hallmark effect: evading apoptosis.

Primary targets

CDK4_CYCLIN_D3DYRK3PIM3CAMK2ACLK1

Top hallmarks

  • evading apoptosis5.6k
  • proliferation5.4k
  • tumor promoting inflammation5.1k

Top pathways disrupted

  • apoptosis9.4k
  • g2m checkpoint9.3k
  • e2f targets9.3k

Resistance landscape — Abemaciclib

MeasuredReference

No variant annotations found on Abemaciclib's top targets.

No variant annotations on Abemaciclib's top targets.
Open in new tab